Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$92 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-3.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5
Industry P/E
--
EV/EBITDA
-1.4
Div. Yield
0 %
Debt to Equity
-8.9
Book Value
$--
EPS
$-0.8
Face value
--
Shares outstanding
53,464,300
CFO
$-263.10 Mln
EBITDA
$-303.87 Mln
Net Profit
$-295.92 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Milestone Pharmaceuticals (MIST)
| -27.1 | 41.0 | -28.6 | 23.7 | -33.3 | -15.9 | -- |
|
BSE Sensex*
| 4.0 | -1.1 | 8.1 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Milestone Pharmaceuticals (MIST)
| -57.8 | -39.5 | -2.2 | -58.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Milestone Pharmaceuticals (MIST)
|
1.7 | 92.0 | 0.0 | -51.9 | -- | -- | -- | 5.0 |
| 3.5 | 931.3 | 23.1 | -167.9 | -1,294.8 | -16 | -- | 0.9 | |
| 7.9 | 1,099.8 | 247.3 | 39.9 | 7.2 | 10.8 | 30.4 | 3.1 | |
| 3.8 | 156.5 | 0.0 | -27.0 | -- | -65.9 | -- | 4.4 | |
| 2.0 | 14.5 | 0.0 | -5.8 | -- | -66.6 | -- | 2.2 | |
| 1.7 | 75.5 | 0.0 | -28.5 | -- | -23.7 | -- | 0.7 | |
| 7.9 | 225.7 | 30.9 | -14.4 | -33.8 | -- | -- | 57.9 | |
| 31.9 | 2,457.0 | 7.5 | -251.5 | -2,936.8 | -33.5 | -- | 3.5 | |
| 0.1 | 95.4 | 27.5 | -101.6 | -167.9 | -60.6 | -- | 0.3 |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium... channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada. Address: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6 Read more
CEO, President & Director
Mr. Joseph G. Oliveto M.B.A.
CEO, President & Director
Mr. Joseph G. Oliveto M.B.A.
Headquarters
Montreal, QC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Milestone Pharmaceuticals Inc (MIST) stood at $ 75 Mln as on 31-Mar-25
The share price of Milestone Pharmaceuticals Inc (MIST) is $1.72 (NASDAQ) as of 18-Jun-2025 16:01 EDT. Milestone Pharmaceuticals Inc (MIST) has given a return of -33.31% in the last 3 years.
Milestone Pharmaceuticals Inc (MIST) has a market capitalisation of $ 92 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Milestone Pharmaceuticals Inc (MIST) is 4.96 times as on 18-Jun-2025, a 39% premium to its peers’ median range of 3.57 times.
Since, TTM earnings of Milestone Pharmaceuticals Inc (MIST) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Milestone Pharmaceuticals Inc (MIST) and enter the required number of quantities and click on buy to purchase the shares of Milestone Pharmaceuticals Inc (MIST).
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada. Address: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
The CEO & director of Mr. Joseph G. Oliveto M.B.A.. is Milestone Pharmaceuticals Inc (MIST), and CFO & Sr. VP is Mr. Joseph G. Oliveto M.B.A..
There is no promoter pledging in Milestone Pharmaceuticals Inc (MIST).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
145
|
|
|
86
|
|
|
23
|
|
|
17
|
|
|
15
|
|
|
7
|
|
|
1
|
|
|
328
|
| Milestone Pharmaceuticals Inc. (MIST) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Milestone Pharmaceuticals Inc (MIST) was $0 Mln.
$-0.01
(
